Forward P/S Multiple: iSpecimen Inc (ISPC)

iSpecimen Inc. (ISPC) is developing a scalable digital hub for biomaterial exchange, extracting profit from every transaction without incurring infrastructure costs. The GURU.Markets service features a linear chart of the forward price-to-sales multiple, where 3.70 represents the current level of the metric. This confirms the company's pricing power derived from its unique access to rare samples. The brand's impeccable ethical standing guarantees the trust of the world's leading laboratories.

ISPC iSpecimen Corp: Market Cap to Projected Revenue in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for iSpecimen Inc.

- market price and analyst price targets:

Price Chart iSpecimen|ISPC - Consensus Target

- company stock exchange capitalization indicators:

Market Capitalization ISPC|ISPC - Total Enterprise Value

- issuer book value statistics:

Net Assets per Single Share iSpecimen|ISPC - Accounting Capitalization|Market Cap to Net Assets Ratio ispecimen.com|ISPC - Aggregate Asset Value

- debt and liquidity data:

- business earnings and investment ratios data:

ISPC - Net Financial Result|Expected Profit iSpecimen Inc.|ISPC - Business Payback Period|Future Price to Earnings iSpecimen|ISPC - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple ISPC|ISPC - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) iSpecimen|ISPC - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months ispecimen.com|ISPC - Net earnings per one share growth for the current year|Expected earnings per share growth for next year iSpecimen Inc.

- sales and revenue indicators:

ISPC - Company Sales Revenue|Company Projected Revenue iSpecimen|ISPC - Market Cap to Revenue|Forward P/S Multiple ISPC

Fundamental company valuation:iSpecimen Corp ISPC

Forward P/S determines the market value of one dollar of expected revenue, allowing for an assessment of the asset's current level of overvaluation or discount relative to historical averages. The current value of 3.70 based on the projected P/S reflects market expectations for scaling the commission income of the biospecimen marketplace iSpecimen Inc. (ISPC), serving as an indicator of the business's fundamental stability amid growing demand for medical research.

Competitors of iSpecimen Inc. (ISPC)

Price-to-Projected Revenue Ratio Veeva VEEV|DOCS - Forward Price-to-Revenue Multiple|HealthEquity Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Waystar Corp|CorVel Corporation (CRVL) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue PRVA|Forward Price-to-Revenue Multiple HURN|CERT: Forward Price to Sales|Forward P/S Multiple OMCL|Market Cap to Expected Sales Ratio GoodRx Gold|Price-to-Projected Revenue Ratio Schrodinger, Inc. SDGR|PHR: Market Cap to Projected Revenue|Omada Health - Forward P/S Multiple|Evolent Health Inc (EVH) - Forward Price-to-Revenue Multiple|HSTM (HealthStream Corp) - Forward Price-to-Revenue Multiple|DH - Market Cap to Expected Sales Ratio|CCSI (Consensus Cloud Solutions) - Forward P/S Multiple|agilonhealth.com (AGL) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Absci Corporation (ABSI)|Market Cap to Expected Sales Ratio So-Young International Inc|Price-to-Projected Revenue Ratio National Research Corporation NRC|SPOK (USA Mobility) - Future Price to Revenue|OptimizeRx Corporation - Forward P/S Multiple|trubridge.com (TBRG) - Forward Price-to-Revenue Multiple|SLP: Forward P/S Multiple|SOPH - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple HCAT|CCLD (CareCloud Corp) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple RSSS (Research Solutions)|DLHC (dlhcorp.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio OneMedNet ONMD|SCNX - Forward Price-to-Revenue Multiple|Healthcare Triangle Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Bullfrog AI Holdings|WORX: Forward P/S Multiple|Market Cap to Projected Revenue MSPR|ICCT (iCoreConnect, Inc.) - Forward P/S Multiple|TRxADE HEALTH Inc (MEDS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Orgenesis Corp (ORGS)|Market Cap to Expected Sales Ratio r1rcm.com|Price-to-Projected Revenue Ratio Sharecare, Inc. SHCR|STRM (streamlinehealth.net) - Future Price to Revenue|Syra Health - Forward P/S Multiple|Market Cap to Future Revenue Ratio Apollo Medical Holdings|MODN: Forward P/S Multiple|Forward Price-to-Revenue Multiple NextGen Healthcare Corp